We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00795457
First Posted: November 21, 2008
Last Update Posted: July 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Oncovir, Inc.
Information provided by (Responsible Party):
Ian F. Pollack, M.D., University of Pittsburgh
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)